Yinka Sowemimo-Coker, a 65-year-old mother, survived pancreatic cancer after medical professionals missed her diagnosis for an entire year. Despite severe symptoms and three hospital visits, she only received treatment after a friend urged her to seek a second opinion.
From Anaemia to Liver Infections: The Year Yinka Sowemimo-Coker Was Ignored
The medical journey of Yinka Sowemimo-Coker began in early 2018 when she experienced profuse sweating after climbing stairs, a symptom the report identifies as a little-known red flag for pancreatic cancer. Despite this and agonizing back pain that radiated toward her stomach, her first hospital admission resulted in a diagnosis of iron deficient anaemia. As the report says, she was discharged just two days later , leaving the underlying cause of her distress unadressed.
Eight months later, Yinka Sowemimo-Coker returned to the hospital with the same symptoms, but this time doctors suspected a liver infection. Even as her condition deteriorated into a dangerously high fever by January 2019, she was treated with paracetamol and told to return for a blood transfusion. By this stage, the physical toll was undeniable; Yinka Sowemimo-Coker had dropped from a dress size 20 to a size 6 and was suffering from jaundice and extreme weakness.
The 3% Survival Window and the 'Silent Killer's' Toll
Pancreatic cancer is frequently termed the "silent killer" because it often presents few early symptoms, making late-stage diagnosis common. According to Pancreatic Cancer UK, roughly 93 per cent of patients die from the disease within five years of their diagnosis. The lethality is such that only one in four patients survive beyond the first year.
For Yinka Sowemimo-Coker, the delay in diagnosis was nearly fatal. When a tumour was finally discovered following a second opinion and a three-week hospital stay, she was informed that her chance of surviving the year was approximately three per cent. This stark statistic underscores the critical importance of timely intervention in cases where symptoms are vague or easily misattributed to other conditions.
Irreversible Electroporation and the Path to Remission
On February 14, 2019, Yinka Sowemimo-Coker underwent a specialized surgical procedure using a technique called irreversible electroporation. This method involves the removal of tissue to destroy cancerous cells, a move that doctors later described as a lucky catch, noting that any further delay would have rendered surgery impossible.
Following the surgery and six months of chemotherapy, Yinka Sowemimo-Coker was declared to be in remission by the end of 2019.. Seven years after her initial diagnosis, she remains in good health with clear scans, though she continues to undergo two check-ups annually to monitor her status. in response to her ordeal, she established the charity DChanger to support other cancer patients.
The 20% Rise in UK Diagnoses and the Shift Toward Younger Women
The case of Yinka Sowemimo-Coker mirrors a worrying broader trend in public health. According to the source, diagnoses of pancreatic cancer in the UK have increased by approximately one-fifth since the 1990s. This rise is being driven specifically by an increase in cases among women under the age of 55.
While the exact causees of most cases remain unknown, clinical data links an increased risk to smoking, being overweight, and the consumption of red meat. The NHS advises that while back pain and sweating are common, they should be treated as urgent if they persist alongside unexplained weight loss, fatigue, sudden onset diabetes, or bowel changes.
The Mystery of Pancreatic Causes and Limited Clinical Trial Access
Despite the rising number of cases, significant gaps remain in the medical community's understanding of the disease. Dina Jupp, the chief executive of Pancreatic Cancer UK, notes that doctors still do not know what causes the majority of pancreatic cancer cases, leaving a void in preventative care.
Furthermore, a critical bottleneck exists in treatment options. Dina Jupp has highlighted that access to clinical trials for pancreatic cancer is "appallingly low," which denies many patients the opportunity to access experimental therapies that could extend their lives. This lack of access, combined with the tendency to misdiagnose early symptoms, creates a perilous environment for patients.
Comments 0